Drugs / PhageBank™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05269121 | Sep 2022 → Nov 2023 | periprosthetic joint infection | Adaptive Phage Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PhageBank | “PhageBank™ phage therapy” NCT05269121 ↗ |
| Route | Intravenous | “intravenous (IV) PhageBank™ bacteriophage therapy” NCT05269121 ↗ |